mTOR-inhibiting medicine · Fact sheet
Sirolimus
Also known as rapamycin · Rapamune
Sirolimus is FDA approved for specific transplant and lymphangioleiomyomatosis uses—not to slow aging or extend life. Small healthy-aging trials are exploratory, while approved labeling documents major infection, malignancy, metabolic, lung, wound-healing, and interaction risks.
What is Sirolimus?
Sirolimus is a macrolide medicine that inhibits mTOR, a signaling pathway involved in growth, nutrient sensing, immunity, and cell maintenance.
Rapamycin extends lifespan in several animal models, but translating that finding to healthy humans requires outcomes trials and careful safety testing.
Benefits & claims
mTOR is a central geroscience target, making sirolimus one of the most discussed drug-repurposing candidates in longevity research.
The same immune and growth pathways that make it scientifically interesting also explain why benefits cannot be considered separately from risk.
What the evidence supports
- Small aging trials suggest that controlled research is feasible and have reported selected exploratory signals.
- The PEARL trial did not establish a general longevity benefit and its primary visceral-fat outcome was not significantly improved overall.
Research areas
- Organ-transplant immunosuppression
- Lymphangioleiomyomatosis
- Immune aging and vaccine response
- Physical function and biological-aging measures
Dosage & frequency
Product-specific label informationRapamune has monitored transplant and lymphangioleiomyomatosis regimens. These do not establish an intermittent anti-aging schedule.
Rapamune: lymphangioleiomyomatosis
Patients with lymphangioleiomyomatosis
- Amount
- 2 mg starting daily amount; adjusted to whole-blood trough concentrations 5–15 ng/mL
- Frequency
- Once daily
- Route studied or labeled
- Oral
Therapeutic drug monitoring; not a transplant or longevity schedule.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Whole-blood trough monitoring is part of approved clinical use.
Interactions & precautions
- CYP3A4/P-gp inhibitors or inducers, grapefruit, and cyclosporine can substantially alter sirolimus exposure.
What is still unresolved
- A longevity regimen with a favorable long-term benefit–risk balance remains unestablished.
Side effects & risks
- Approved labeling carries boxed warnings and describes increased susceptibility to infection and possible development of malignancies.
- Other important risks include high cholesterol and triglycerides, impaired wound healing, mouth inflammation, blood-cell changes, lung toxicity, kidney-related concerns, and extensive drug interactions.
- Risk in closely monitored transplant or rare-disease care cannot be assumed acceptable for a healthy person seeking longevity.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Strong human evidence for approved usesEvidence is strong for labeled medical uses, where monitoring and risk management are part of care. Healthy-aging evidence consists of small feasibility and exploratory trials without proof of longer life or prevention of age-related disease.
Studies
Exploratory controlled trial that did not prove longevity or broad healthspan benefit.
Small randomized study focused on feasibility and selected physiological outcomes.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Appetite: reported experiences
Brief improvement followed by persistent symptoms
An author with long COVID described slight early improvement, then mouth ulcers, acne, pronounced fatigue, breast pain, hunger and digestive symptoms. Fatigue later returned to its prior baseline after stopping.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 1 mg initially; later 2 mg, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- About six weeks before stopping
Pre-existing illness and fluctuating symptoms complicate attribution. This account does not verify that rapamycin caused every symptom or the author's proposed immune explanation.
Read the original accountEnergy: reported experiences
Brief improvement followed by persistent symptoms
An author with long COVID described slight early improvement, then mouth ulcers, acne, pronounced fatigue, breast pain, hunger and digestive symptoms. Fatigue later returned to its prior baseline after stopping.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 1 mg initially; later 2 mg, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- About six weeks before stopping
Pre-existing illness and fluctuating symptoms complicate attribution. This account does not verify that rapamycin caused every symptom or the author's proposed immune explanation.
Read the original accountPain: reported experiences
Brief improvement followed by persistent symptoms
An author with long COVID described slight early improvement, then mouth ulcers, acne, pronounced fatigue, breast pain, hunger and digestive symptoms. Fatigue later returned to its prior baseline after stopping.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 1 mg initially; later 2 mg, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- About six weeks before stopping
Pre-existing illness and fluctuating symptoms complicate attribution. This account does not verify that rapamycin caused every symptom or the author's proposed immune explanation.
Read the original accountPerceived benefits alongside mouth sores and higher lipids
In a year-long self-experiment, an author described less shoulder pain and better dental health, but recurrent mouth sores, occasional acne, early ear and eye irritation and higher reported blood lipids.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 6 mg at the time of the summary, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- More than one year
The author acknowledged possible placebo effects and has a public peptide-related platform. Laboratory results and dental assessments were not independently verified; this is not evidence of an anti-aging benefit.
Read the original accountDigestion: reported experiences
Brief improvement followed by persistent symptoms
An author with long COVID described slight early improvement, then mouth ulcers, acne, pronounced fatigue, breast pain, hunger and digestive symptoms. Fatigue later returned to its prior baseline after stopping.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 1 mg initially; later 2 mg, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- About six weeks before stopping
Pre-existing illness and fluctuating symptoms complicate attribution. This account does not verify that rapamycin caused every symptom or the author's proposed immune explanation.
Read the original accountSkin: reported experiences
Brief improvement followed by persistent symptoms
An author with long COVID described slight early improvement, then mouth ulcers, acne, pronounced fatigue, breast pain, hunger and digestive symptoms. Fatigue later returned to its prior baseline after stopping.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 1 mg initially; later 2 mg, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- About six weeks before stopping
Pre-existing illness and fluctuating symptoms complicate attribution. This account does not verify that rapamycin caused every symptom or the author's proposed immune explanation.
Read the original accountPerceived benefits alongside mouth sores and higher lipids
In a year-long self-experiment, an author described less shoulder pain and better dental health, but recurrent mouth sores, occasional acne, early ear and eye irritation and higher reported blood lipids.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 6 mg at the time of the summary, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- More than one year
The author acknowledged possible placebo effects and has a public peptide-related platform. Laboratory results and dental assessments were not independently verified; this is not evidence of an anti-aging benefit.
Read the original accountSensory changes: reported experiences
Perceived benefits alongside mouth sores and higher lipids
In a year-long self-experiment, an author described less shoulder pain and better dental health, but recurrent mouth sores, occasional acne, early ear and eye irritation and higher reported blood lipids.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 6 mg at the time of the summary, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- More than one year
The author acknowledged possible placebo effects and has a public peptide-related platform. Laboratory results and dental assessments were not independently verified; this is not evidence of an anti-aging benefit.
Read the original accountOral health: reported experiences
Occasional mouth sores, otherwise little noticeable change
A commenter described more than a year of rapamycin use with occasional mouth sores and no other noticeable symptoms.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 6 mg, as reported
- Frequency
- Once weekly
- Route
- Not specified clearly
- Duration
- More than one year
Health history and monitoring were not provided. Absence of a noticeable symptom cannot establish safety or an invisible longevity benefit.
Read the original accountBrief improvement followed by persistent symptoms
An author with long COVID described slight early improvement, then mouth ulcers, acne, pronounced fatigue, breast pain, hunger and digestive symptoms. Fatigue later returned to its prior baseline after stopping.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 1 mg initially; later 2 mg, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- About six weeks before stopping
Pre-existing illness and fluctuating symptoms complicate attribution. This account does not verify that rapamycin caused every symptom or the author's proposed immune explanation.
Read the original accountPerceived benefits alongside mouth sores and higher lipids
In a year-long self-experiment, an author described less shoulder pain and better dental health, but recurrent mouth sores, occasional acne, early ear and eye irritation and higher reported blood lipids.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 6 mg at the time of the summary, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- More than one year
The author acknowledged possible placebo effects and has a public peptide-related platform. Laboratory results and dental assessments were not independently verified; this is not evidence of an anti-aging benefit.
Read the original accountCholesterol: reported experiences
Perceived benefits alongside mouth sores and higher lipids
In a year-long self-experiment, an author described less shoulder pain and better dental health, but recurrent mouth sores, occasional acne, early ear and eye irritation and higher reported blood lipids.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 6 mg at the time of the summary, as reported
- Frequency
- Weekly
- Route
- Not specified clearly
- Duration
- More than one year
The author acknowledged possible placebo effects and has a public peptide-related platform. Laboratory results and dental assessments were not independently verified; this is not evidence of an anti-aging benefit.
Read the original accountNo clear change: reported experiences
Occasional mouth sores, otherwise little noticeable change
A commenter described more than a year of rapamycin use with occasional mouth sores and no other noticeable symptoms.
Reported use in this account
- Product
- Product labeled rapamycin
- Amount
- 6 mg, as reported
- Frequency
- Once weekly
- Route
- Not specified clearly
- Duration
- More than one year
Health history and monitoring were not provided. Absence of a noticeable symptom cannot establish safety or an invisible longevity benefit.
Read the original accountApproval status
FDA-approved sirolimus products have specific indications, including prevention of organ rejection in selected kidney-transplant patients and treatment of lymphangioleiomyomatosis. Aging and longevity are not approved indications.
Approved uses
- Specific transplant and lymphangioleiomyomatosis uses described in current FDA-approved labeling
FDA approved for non-aging indications
Sirolimus is FDA approved under Rapamune labeling for defined medical uses. Healthy-aging or longevity use remains investigational and should not be folded into the approval.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether sirolimus can extend healthy human lifespan
- Whether any aging-related benefit outweighs immune, metabolic, and other harms
- Which biomarkers are meaningful rather than merely responsive
- Long-term outcomes in healthy or near-healthy populations
Summary
Sirolimus has approved uses and serious labeled risks. Longevity benefits in healthy people remain unproven.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA prescribing information: Rapamune
Official indications, boxed warnings, contraindications, adverse reactions, and interactions.
- pubmedPEARL randomized trial of sirolimus in healthy aging
Exploratory controlled trial that did not prove longevity or broad healthspan benefit.
- pubmedPilot sirolimus study in older adults
Small randomized study focused on feasibility and selected physiological outcomes.